Company intelligence / Profile preview
Scenic Biotech
Amsterdam, Netherlandsscenicbiotech.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Preclinical
01
Overview
Scenic Biotech has demonstrated positive preclinical results for its lead QPCTL inhibitor SC‑2882 in diffuse large B-cell lymphoma models, showing anti-tumor activity and immune modulation. Three additional programs targeting rare genetic disorders are advancing toward IND-enabling studies. The company’s proprietary Cell-seq platform underpins a robust pipeline of first-in-class small molecule therapies based on the concept of genetic modifier intervention.
- Therapeutic areas
- OncologyRare DiseasesMetabolic Disorders
- Modalities
- Small moleculesGenetic modifiers/modifier therapy
- Industry
- Biotech
02
Drug pipeline
7 assets6 more assets in the full pipeline.
Request access →03
Partnerships
Genentech/Roche – multi-year collaboration on target discovery/development using Cell-seq platform; expanded twice since inception in September 2020.Bristol Myers Squibb – research collaboration announced April 2024 focused on drug target identification for indication selection/expansion using Cell-seq technology.
Beyond the preview
Go deeper on Scenic Biotech.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Scenic Biotech.